8:00 am

Welcome
Morton Coleman, MD

8:05 am

Introduction
John P. Leonard, MD

8:10 am

Tumor microenvironment and lymphoma pathogenesis
Jia Ruan, MD, PhD

8:30 am

Targeting epigenetics as lymphoma therapy
Ari Melnick, MD

8:50 am

Panel discussion

9:00 am

Epidemiologic aspects of lymphoma: How can it help us manage our patients?
Thomas Habermann, MD

9:20 am

Is radiation an anachronism in Hodgkin’s disease?
George Canellos, MD

9:40 am

ABVD vs. BEACOPP: Can we tailor therapy to fit the patient?
Ann LaCasce, MD

10:00 am

Panel discussion

10:15 am

Coffee break

10:45 am

What’s new in T cell lymphoma
Rebecca Elstrom, MD

11:05 am

Sorting through the options for initial management of mantle cell lymphoma
Michael Williams, MD

11:25 am

How to treat MALT lymphoma failing antibiotics
Andrew Zelenetz, MD

11:45 am

Presentation of the best Lymphoma abstract Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma
Myron S. Czuczman, MD, PhD

11:55 pm

Lunch symposium
Nursing Perspectives on Mastering Challenging Patient Cases in Lymphoma and Multiple Myeloma
Supported by Millennium Pharmaceuticals, Inc.

2:00 pm

Is there a gold standard for the frontline therapy of FL?
David Maloney, MD, PhD

2:20 pm

What are the most promising new agents for B cell lymphoma?
John P. Leonard, MD

2:40 pm

Who should we treat with CNS prophylaxis in DLBCL?
Peter Martin, MD

2:55 pm

Panel discussion

3:05 pm

Coffee break

3:25 pm

What is the best initial therapy for Burkitt’s lymphoma?
John Sweetenham, MD

3:45 pm

Optimal initial management of DLBCL
Jane Winter, MD

4:05 pm

Imaging patients with DLBCL: More, less, how?
Rebecca Elstrom, MD

4:25 pm

Treatment of elderly patients with relapsing DLBCL
Morton Coleman, MD

4:45 pm

Panel discussion

4:55 pm

Adjourn